Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene ...

Is EDIT a buy now?

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...

Discover historical prices for EDIT stock on Yahoo Finance. View daily, weekly or monthly format back to when Editas Medicine, Inc. stock was issued.